Your browser doesn't support javascript.
loading
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer.
Bancaro, Nicolò; Calì, Bianca; Troiani, Martina; Elia, Angela Rita; Arzola, Rydell Alvarez; Attanasio, Giuseppe; Lai, Ping; Crespo, Mateus; Gurel, Bora; Pereira, Rita; Guo, Christina; Mosole, Simone; Brina, Daniela; D'Ambrosio, Mariantonietta; Pasquini, Emiliano; Spataro, Clarissa; Zagato, Elena; Rinaldi, Andrea; Pedotti, Mattia; Di Lascio, Simona; Meani, Francesco; Montopoli, Monica; Ferrari, Matteo; Gallina, Andrea; Varani, Luca; Pereira Mestre, Ricardo; Bolis, Marco; Gillessen Sommer, Silke; de Bono, Johann; Calcinotto, Arianna; Alimonti, Andrea.
Afiliación
  • Bancaro N; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Calì B; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Troiani M; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Elia AR; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Arzola RA; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Attanasio G; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Lai P; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Crespo M; The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Gurel B; The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Pereira R; The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Guo C; The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Mosole S; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Brina D; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • D'Ambrosio M; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Pasquini E; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Spataro C; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Zagato E; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Rinaldi A; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland.
  • Pedotti M; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland; Institute for Research in Biomedicine (IRB), 6500 Bellinzona, Switzerland.
  • Di Lascio S; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland; Institute of Oncology of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
  • Meani F; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland; Institute of Oncology of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
  • Montopoli M; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy; Veneto Institute of Molecular Medicine, Padova, Italy.
  • Ferrari M; Department of Urology, Ente Ospedaliero Cantonale, Ospedale Regionale di Lugano - Civico USI - Università della Svizzera Italiana, Lugano, Switzerland.
  • Gallina A; Department of Urology, Ente Ospedaliero Cantonale, Ospedale Regionale di Lugano - Civico USI - Università della Svizzera Italiana, Lugano, Switzerland.
  • Varani L; Institute for Research in Biomedicine (IRB), 6500 Bellinzona, Switzerland.
  • Pereira Mestre R; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland; Institute of Oncology of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
  • Bolis M; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland; Computational Oncology Unit, Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche 'Mario Negri', Via Mario Negri 2, 20156 Mil
  • Gillessen Sommer S; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland; Institute of Oncology of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
  • de Bono J; The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Calcinotto A; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland. Electronic address: arianna.calcinotto@ior.usi.ch.
  • Alimonti A; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, 6900 Lugano, Switzerland; Institute of Oncology of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland; Veneto Institute of Molec
Cancer Cell ; 41(3): 602-619.e11, 2023 03 13.
Article en En | MEDLINE | ID: mdl-36868226
Tumor cells promote the recruitment of immunosuppressive neutrophils, a subset of myeloid cells driving immune suppression, tumor proliferation, and treatment resistance. Physiologically, neutrophils are known to have a short half-life. Here, we report the identification of a subset of neutrophils that have upregulated expression of cellular senescence markers and persist in the tumor microenvironment. Senescent-like neutrophils express the triggering receptor expressed on myeloid cells 2 (TREM2) and are more immunosuppressive and tumor-promoting than canonical immunosuppressive neutrophils. Genetic and pharmacological elimination of senescent-like neutrophils decreases tumor progression in different mouse models of prostate cancer. Mechanistically, we have found that apolipoprotein E (APOE) secreted by prostate tumor cells binds TREM2 on neutrophils, promoting their senescence. APOE and TREM2 expression increases in prostate cancers and correlates with poor prognosis. Collectively, these results reveal an alternative mechanism of tumor immune evasion and support the development of immune senolytics targeting senescent-like neutrophils for cancer therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Apolipoproteínas E / Neoplasias de la Próstata Límite: Animals / Humans / Male Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Apolipoproteínas E / Neoplasias de la Próstata Límite: Animals / Humans / Male Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Suiza